MARKET

BBIO

BBIO

Bridgebio Pharma
NASDAQ
77.87
+3.28
+4.40%
After Hours: 77.59 -0.28 -0.36% 19:45 04/13 EDT
OPEN
74.87
PREV CLOSE
74.59
HIGH
79.25
LOW
74.59
VOLUME
2.59M
TURNOVER
--
52 WEEK HIGH
84.94
52 WEEK LOW
31.77
MARKET CAP
15.10B
P/E (TTM)
-20.5733
1D
5D
1M
3M
1Y
5Y
1D
BridgeBio Oncology Therapeutics grants inducement stock options for 32,675 shares at $8.4
PUBT · 8h ago
Weekly Report: what happened at BBIO last week (0406-0410)?
Weekly Report · 18h ago
Assessing BridgeBio Pharma (BBIO) Valuation After Key ATTR-CM And LGMD2I/R9 Milestones
Simply Wall St · 20h ago
CANC: I Give A Hold Rating To This ETF That Invests In Cancer-Fighting Stocks
Seeking Alpha · 3d ago
BridgeBio Pharma Data Updates Shift Focus To Rare Disease Pipeline Potential
Simply Wall St · 3d ago
ClearBridge SMID Cap Growth initiates new positions, exits several in Q1
Seeking Alpha · 4d ago
BridgeBio Pharma Initiated at Outperform by RBC Capital
Dow Jones · 4d ago
BridgeBio Pharma Price Target Announced at $100.00/Share by RBC Capital
Dow Jones · 4d ago
More
About BBIO
BridgeBio Pharma, Inc. is a biopharmaceutical company. It discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. It also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease.

Webull offers BridgeBio Pharma Inc stock information, including NASDAQ: BBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BBIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BBIO stock methods without spending real money on the virtual paper trading platform.